Pfizer, AstraZ COVID-19 shots provide a better immune response when mixed with Modern

By Pushkala Aripaka and Lucy Marks

(Reuters) – A major UK research into COVID-19 vaccines has found that people had a better immune response when they received the first dose of AstraZeneca (NASDAQ 🙂 or Pfizer-BioNTech and beyond. Modern (NASDAQ 🙂 Nine weeks later, according to Monday’s results.

“We’ve found a very good immune response around the world … in fact, the Oxford-AstraZeneca vaccine is more than the threshold set for two doses,” Matthew Snape, an Oxford professor behind the Com-COV2 trial, told Reuters.

Findings that support a flexible dose will offer hope to poor middle-income countries and should combine different brands between the foreground and the background if supply is scarce or becomes unstable.

“I believe the data in this study will be particularly interesting and valuable for low- and middle-income countries where the first two doses of vaccines are still being rolled out,” Snap said.

“We’re showing you that you don’t have to be rigid about getting the same vaccine for a second dose.

If the AstraZeneca-Oxford vaccine comes Modern or later Novavax (NASDAQ 🙂 triggered the shot, higher antibodies and T-cell responses compared to the two doses of AstraZeneca-Oxford, according to researchers at Oxford University.

A study of 1,070 volunteers also found that a dose of the Pfizer-BioNTech vaccine was better than two doses of the Pfizer-BioNTech course after a modern shot.

Pfizer-BioNTech and then Novavax produced two higher doses of antibodies than the Oxford-AstraZeneca program, although this program resulted in two lower doses of antibodies and T cell responses than the two Pfizer-BioNTech programs.

No security concerns were raised, according to a study by Oxford University published in the Lancet medical journal.

Many countries have spread a mix of robust data before it became available, with nations with high numbers of infections, low supplies and slow immunization due to some security issues.

The duration of protection provided by vaccines is being studied, including booster doses in increasing cases. New variants, including Delta and Omicron, have now increased the pressure to accelerate vaccination campaigns.

Participants ’blood samples were tested against Wild-Type, Beta, and Delta variants, researchers in the Com-COV2 study said, adding that the effectiveness of vaccines against the variants had been lowered, but this was consistent across mixed courses.

Dissemination of vaccines using technology from different platforms, for example Pfizer (NYSE 🙂 and Modern’s mRNA, AstraZeneca’s viral vector, and Novavax’s protein-based shot – and it’s new at the same time.

The results may suggest new approaches to immunization against other diseases, he said.

The study also found that the first dose of the AstraZeneca-Oxford vaccine elicited a particularly strong response after any other candidate in the study, in line with the June findings.

The study was designed as a “non-inferiority” study – intended to prove significantly worse than standard mixing programs – and compares the immune system’s responses to the gold responses reported in previous clinical trials. each vaccine.